Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Heinz Gisslinger, Christine Beham‐Schmid et al.|American Journal of Hematology|2017Cited by 66
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical dataMartin Schalling, Heinz Gisslinger, Andreas Gleiß et al.|Blood Cancer Journal|2017Cited by 20
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study ResultsHeinz Gisslinger, Christoph Klade, Veronika Buxhofer‐Ausch et al.|Blood|2018Cited by 18
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsJean‐Jacques Kiladjian, Christoph Klade, Francisca Ferrer‐Marín et al.|Annals of Hematology|2024Cited by 14
Ruxolitinib therapy for myelofibrosis in AustriaMaria‐Theresa Krauth, Heinz Gisslinger, Sonja Burgstaller et al.|Wiener klinische Wochenschrift|2018Cited by 6